Search
Human papillomavirus type 52 L1 capsid protein antigen
go.drugbank.com/drugs/DB10313ApprovedInvestigational(VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles
Flufenamic acid
go.drugbank.com/drugs/DB02266ApprovedIt is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Lormetazepam
go.drugbank.com/drugs/DB13872ApprovedIt is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.
Regdanvimab
go.drugbank.com/drugs/DB16405ApprovedWithdrawn[A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]
Pepsin
go.drugbank.com/drugs/DB13198ApprovedWithdrawnSoon afterward, it was shown that these protein nutrients were cleaved by pepsin to products called _peptones_ [A32603]. … Pepsin is approved by the FDA and is used in food at levels not to exceed current good manufacturing practice [L2363].
Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationalIntravenous indometacin is administered to close a hemodynamically significant patent ductus arteriosus, as indicated by clinical evidence, in premature infants. … Indometacin was first discovered in 1963 and it was first approved for use in the U.S. by the Food and Drug Administration in 1965, [A486] along with other acetic acid derivatives such as [diclofenac]
Dasiglucagon
go.drugbank.com/drugs/DB15226ApprovedIt is characterized by neurological impairment, with manifestations like loss of consciousness and seizure. … [L39195] The approval of dasiglucagon marks the first glucagon analog approved for severe hypoglycemia treatment that does not require administration by a healthcare professional.[L39195]
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalMyasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … [L39509] By antagonizing this interaction, efgartigimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against
Rofecoxib
go.drugbank.com/drugs/DB00533ApprovedWithdrawnOn September 30, 2004, Merck voluntarily withdrew rofecoxib from the market because of concerns about increased risk of heart attack and stroke associated with long-term, high-dosage use.
Dimercaprol
go.drugbank.com/drugs/DB06782ApprovedDimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II.